Snitched from PharmaTimes:
Prior activation of human T-cells could be the reason for the severe adverse reactions triggered by TeGenero's monoclonal antibody TGN1412 in a Phase I trial at London's Northwick Park Hospital last March.

The hypothesis is based on research by a team from Imperial College London, King's College London and the Cambridge- ( Read more... )